Pioglitazone On DSS Induced Inflammatory Bowel Disease In Mice Serum TNF-α And Hs-CRP Levels

BackgroundInflammatory bowel disease(IBD), including ulcerative colitis(UC) and Crohn’sdisease(CD), is a kind of level in colorectal mucosa submucosa nonspecificinflammation characteristic of the disease. In recent years the incidence of IBD wererising trend year by year, because of its long illness, illness repeatedly, and affect thepatients quality of life seriously, social medical economic burden. The etiologyandpathogenesis of IBD remains unclear, the study found that are closely related with thegenetic susceptibility, environmental factors, and immune abnormalities. The tumordeath factor alpha (TNF–α) is still the best biological markers of inflammatory boweldisease,and inflammatory bowel disease can detect the rise of TNF–αand IL–6.Theinflammation factor can endothelial injury and increase the risk of coronary heartdisease by vascular, and inflammatory bowel disease increaseing the risk of coronaryheart disease also have related reports. The incidence of inflammatory bowel diseaseis higher in the European and American countries, and rates are relatively low in ourcountry, although people gradually deep understanding of inflammatory boweldisease, its may cause complications,we also know not much, so we should take anactive treatment and prevention in the early stages of the disease. Serumhypersensitive c-reactive protein (hypersensitive c-reactiveprotein, hs-CRP) ispredicting the markers of disease of heart head blood-vessel, and is a risk factor for atherosclerosis.Coronary heart disease (Coronary heart diseases, CHD) is a kind ofcomplex diseases seriously that affect human health, its pathological physiologicalprocess is relatively complex. About50﹪of hyperlipidemia in clinically appear inpatients with coronary heart disease,however，the pathogenesis of coronary heartdisease is not very clear, generally considered to be more than a factor and themulti-stage process.Atherosclerosis (atherosclerosis, AS) is the main cause ofcoronary heart disease that has been recognised by the medical profession, andinflammatory reaction in the formation of atherosclerosis plays an important role, thatcan affect the formation and development of plaque. The gene polymorphisms ofinflammatory markers, according to new research, moreover, not only can theseinflammatory cytokines gene polymorphism by influencing itself, can also affectother cytokine expression level and biological activities, so as to promote theoccurrence and development of coronary heart disease (CHD). Pioglitazone(Pioglitazone, PG) are TZDS compounds, the compounds are synthetic ppar-gammaligand.Now find the drug not only have fall blood sugar, resisting action such asatherosclerosis, reducing blood fat, but also have the function of the control ofinflammatory disease, which affects the level of the serum TNF-αand hs–CRP.Ppar-gamma ligands can inhibit the NF-κB transcription activity and NF-κB ofDNA binding activity, through the inhibition of NF-κB signaling pathways aspotential drugs for the treatment of inflammatory bowel disease.ObjectiveBy observing the pioglitazone for inflammatory bowel disease in mice serumTNF-αand Hs-CRP level, Explore the pioglitazone treatment of inflammatorybowel disease and reduce the long-term risk for atherosclerosis.MethodsClean BALB/c mice were randomly divided into3groups, respectively, the normal group(n=15), model group (n=15), pioglitazone drug intervention group(n=15), with3%DSS solution preparation of inflammatory bowel disease in micemodel (26only building success, success rate86%),2days build mold forpioglitazone25mg/kg to fill the stomach, once a day, until the end of the experiment.After the treatment, observing the intestinal tissue in mice by HE pathologicalmorphological changes, using enzyme-linked immunoassay (ELISA) to detect serumhs-CRP and TNF-α, By observing the pioglitazone for inflammatory bowel disease inmice serum TNF-αand Hs-CRP level, Explore the pioglitazone treatment ofinflammatory bowel disease and reduce the long-term risk for atherosclerosis.Results1. Compared with normal group, model group mice intestine tissue inflammationin sexual behavior, serum hs-CRPand TNF-α levels were significantly increased,and the difference was statistically significant (P <0.001).2. Compared with model group, pioglitazone significantly reduce interventiongroup mice intestinal inflammation performance, and serum hs-CRPand TNF-α levelswere significantly lower, and difference was statistically significant (P <0.001).Conclusion1. The level of serum TNF-α and hs-CRP increased significantly ininflammatory bowel disease group.2. Pioglitazone can cut in inflammatory bowel disease in mice the expression ofTNF-α, reduce intestinal inflammatory change, and improve the intestinal tissuemorphological structure, and play therapy. Pioglitazone significantly decreased theserum hs-CRP levels, so as to reduce the long-term risk for atherosclerosis.